A
Aelin Therapeutics
Develops peptide-based therapeutics that induce targeted protein aggregation to neutralise disease-causing proteins
About Aelin Therapeutics
Aelin Therapeutics, founded in 2017 as a spin-off from VIB and partner universities KU Leuven, VUB, and UGent, is a privately held Belgian company. The company has secured a 27 million Euro Series A investment from a reputable investor syndicate. Aelin Therapeutics specializes in developing Pept-ins™ technology, a novel class of peptide-based therapeutics designed to target high-value undruggable proteins. These proteins are often involved in diseases such as cancer, where traditional drug modalities have failed. The company leverages its unique mode of action, designability, and intracellular target space to create effective treatments. Pept-ins™ can be tailored to target either a single protein or an entire family of proteins, offering broad applicability. Proofs of concept have demonstrated the technology's potential in functional knockdown of mammalian, bacterial, viral, and fungal protein targets for the treatment of human diseases. Aelin Therapeutics operates in the biotechnology and pharmaceutical markets, primarily serving clients in the healthcare sector. The business model focuses on research and development, with revenue generated through partnerships, licensing agreements, and potential future product sales.
Source: Dealroom company dataAt a glance
- Status
- Closed
- Employees
- 20
- Open positions
- None listed
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Oncology, Spinout, Biotech and Pharma, Digital Pharma, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Dec 2017 | $30M | $119M | FundPlus · Boehringer Ingelheim Venture Fund · PMV · Novartis Venture Fund | ↗ |
| SPINOUT✓Other financing | Jan 2017 | $0 | — | Ghent University · Flanders Institute for Biotechnology · KU Leuven | — |
Growth signals
Latest recorded traffic for Aelin Therapeutics is 0 monthly website visits. Aelin Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Aelin Therapeutics in the Leuven ecosystem
The Aelin Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
EQT Life Sciences
FundPlus
Boehringer Ingelheim Venture Fund
PMV
Novartis Venture Fund
Other known investors4 additional known investors
Flanders Institute for Biotechnology
Ghent University
KU Leuven
Gemma Frisius Fund - GFF
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Aelin Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Aelin Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









